VELOSEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELOSEF (VELOSEF).
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
| Metabolism | Not significantly metabolized; primarily excreted unchanged in urine via glomerular filtration and tubular secretion. |
| Excretion | Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); small biliary/fecal (5-10%) |
| Half-life | 1-2 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min) |
| Protein binding | 10-20% bound to serum albumin |
| Volume of Distribution | 0.3-0.5 L/kg (approximates extracellular fluid volume) |
| Bioavailability | Oral: 70-80% (capsule and suspension); IM: ~90% |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 15-30 minutes; Intravenous: within minutes |
| Duration of Action | 6-8 hours (normal renal function); extended in renal impairment; dose adjustment required |
250-500 mg orally every 6 hours or 1-2 g intramuscularly/intravenously every 6-12 hours for moderate to severe infections.
| Dosage form | TABLET |
| Renal impairment | GFR 10-30 mL/min: 250 mg every 12 hours; GFR <10 mL/min: 250 mg every 24 hours. |
| Liver impairment | No specific Child-Pugh based adjustments; use caution in severe hepatic impairment. |
| Pediatric use | 50-100 mg/kg/day orally divided every 6 hours; 50-100 mg/kg/day intramuscularly/intravenously divided every 6-12 hours. |
| Geriatric use | Dose based on renal function; reduce dose according to GFR as in renal adjustment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VELOSEF (VELOSEF).
| Breastfeeding | VELOSEF is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.02–0.05. It is considered compatible with breastfeeding due to low oral bioavailability in infants, but caution is advised for infants with gastrointestinal disturbances or allergy risk. |
| Teratogenic Risk | Cephalosporins, including VELOSEF, are generally considered low risk in pregnancy. Animal studies have not shown fetal harm, but adequate human studies in pregnant women are lacking. In the first trimester, risk is not established; second and third trimesters are likely safe with no known teratogenic effects. FDA Pregnancy Category B. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to cephalosporin antibiotics or any component of the formulation","Severe immediate hypersensitivity reaction to penicillins (cross-sensitivity)"]
| Precautions | ["Hypersensitivity reactions: cross-allergenicity with penicillins and other cephalosporins","Pseudomembranous colitis: Clostridium difficile-associated diarrhea reported with nearly all antibacterial agents","Renal impairment: dosage adjustment required in patients with significantly reduced renal function","Seizure potential: use with caution in patients with a history of seizures, especially with high doses or renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal adverse effects: gastrointestinal disturbances, hypersensitivity reactions, and superinfection. No specific fetal monitoring required unless maternal condition warrants. Renal function monitoring recommended in preeclampsia or gestational hypertension. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data available; potential for reversible sperm motility inhibition with high doses (theoretical, not clinically significant). |